Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
The Pipeline for New MASLD & MASH Treatments is Promising, says Naim Alkhouri, MD
Following the landmark FDA approval of resmetirom for MASH with fibrosis, hepatologist and researcher Alkhouri describes more mid- and late-stage candidates.
Naim Alkhouri, MD, chief medical officer, chief of transplant hepatology, and director of the fatty liver program at Arizona Liver Health, in Phoenix, said that he and fellow researchers investigating treatments for metabolic dysfunction-associated liver disease, or MASLD, and metabolic dysfunction-associated steatohepatitis, or MASH, have their work cut out for them for a decade, at least. In a recent interview with Patient Care® Alkhouri offered a topline review of molecules currently moving through phase 2 and phase 3 clinical trials.
Other videos in this series with Dr Alkhouri:
A MASLD Mantra to Practice By: Screen, Stage, Treat
The FDA Approval of Resmetirom for MASH Changes Everything—for Patients and their Physicians
Early Detection of MASLD in Primary Care: The Essentials with Naim Alkhouri, MD
The Rate of Undetected MASLD in the US is a Sobering Statistic, says Expert Hepatologist Naim Alkhouri, MD
Related Content
